source
- UniQure to release four-year Huntington’s gene therapy results by SeptemberUniQure, a biotech firm, will report four-year data from its Huntington’s disease gene therapy trial before the end of September. The therapy, AMT-130, has already been submitted to regulators in…
- Encoded Therapeutics secures $275M Series F to push Dravet gene therapy and expand manufacturingEncoded Therapeutics, a biotech focused on neuro‑genetic disorders, announced a $275 million Series F financing round. The capital was co‑led by Google Ventures and an undisclosed healthcare fund,…